A Comprehensive Review of Evolving Paradigms, Technologies, and Global Frameworks on Patient-Centric Pharmacovigilance and Digital Reporting Systems

5.1 Underreporting and Reporting Fatigue

It is estimated that fewer than 10% of ADRs are formally reported in most high-income countries, with rates substantially lower in low- and middle-income countries (LMICs).²⁶ Patient-facing digital tools have partially ameliorated this through improved accessibility; however, reporting fatigue particularly in chronic disease populations who experience frequent adverse effects remains a significant barrier. Longitudinal studies suggest that initial engagement with PV apps decreases markedly after the first three months of use.

5.2 Quality of Patient-Generated Data

Patient-reported ICSRs frequently contain incomplete information regarding drug dosage, indication, concomitant medications, and medical history elements critical for causality assessment. A comparative analysis of MHRA Yellow Card reports found that patient reports had lower data completeness scores than HCP reports across most mandatory data fields.²⁷ However, proponents argue that even incomplete patient reports provide valuable signal-generating information that compensates for their structural limitations.

5.3 Digital Equity and the Digital Divide

Digital reporting tools disproportionately serve younger, more educated, and internet-connected populations, systematically excluding elderly patients, those with low health literacy, and communities in low-resource settings.²⁸ Given that older adults are the most frequent consumers of polypharmacy and the most vulnerable to ADRs, their underrepresentation in digital PV datasets represents a critical public health blind spot requiring targeted multi-channel reporting strategies.

FUTURE DIRECTIONS

6.1 Wearable Technologies and Continuous Monitoring

Wearable devices smartwatches, biosensors, continuous glucose monitors, and implantable devices generate continuous physiological data streams that may enable passive, real-time ADR surveillance. Integration of wearable data with PV systems could automate detection of specific ADR signatures such as QT prolongation (via ECG monitoring), hypoglycaemia (via CGM), or anaphylaxis (via heart rate and galvanic skin response).²⁹

6.2 Electronic Health Record Integration

Routine integration of EHR data with pharmacovigilance databases represents perhaps the most transformative opportunity in digital PV. Initiatives such as the FDA's Sentinel System, which links EHR data from over 100 million patients, have demonstrated the feasibility of active surveillance at population scale.³⁰ The EU's DARWIN EU (Data Analysis and Real World Interrogation Network), launched in 2022, similarly leverages federated EHR databases for regulatory-grade real-world evidence generation including safety surveillance.

6.3 Patient Engagement and Co-Design

Emerging evidence suggests that patient co-design of PV systems involving patients in the development of reporting interfaces, data feedback mechanisms, and communication strategies substantially improves reporting rates and data quality.³¹ Patient advocacy organisations, disease-specific registries, and rare disease networks represent underutilised channels for building patient-centric PV infrastructure, particularly for conditions where formal reporting infrastructure remains weak.

6.4 Blockchain and Data Integrity

Blockchain technology has been proposed as a mechanism for ensuring data integrity, preventing duplicate reports, and maintaining auditable chains of evidence for patient-reported ICSRs.³² While proof-of-concept studies are promising, scalability, interoperability, and regulatory acceptance remain unresolved. The use of smart contracts to automate data sharing agreements between patients, HCPs, and regulatory authorities under transparent governance frameworks represents a longer-term but potentially transformative application.

CONCLUSION

Patient-centric pharmacovigilance, underpinned by digital technologies, represents a fundamental evolution in drug safety science. By recognizing patients as active partners rather than passive subjects of surveillance, the PV community gains access to qualitatively richer, more timely, and more representative safety data. Digital reporting systems from mobile applications to AI-powered signal detection and social media mining have substantially expanded the reach and responsiveness of pharmacovigilance infrastructure. However, the full potential of digital patient-centric PV remains unrealised. Persistent challenges in data quality, health literacy, digital equity, privacy protection, and regulatory harmonization must be systematically addressed through interdisciplinary collaboration among patients, clinicians, data scientists, industry stakeholders, and regulatory agencies. Particular attention must be paid to ensuring that digital advances do not exacerbate existing health inequities by marginalizing vulnerable patient populations.

Future pharmacovigilance systems must be co-designed with patients, underpinned by robust digital infrastructure, and governed by frameworks that balance the imperatives of patient privacy with the public health necessity of comprehensive drug safety monitoring. In this vision, every patient prescribed a medication becomes a potential contributor to the global safety knowledge base transforming pharmacovigilance from a reactive discipline into a proactive, patient-powered science.

REFERENCES

1. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO; 2002. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficacy/pharmvigi/en/
2. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278(7216):1358.
3. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148-56.
4. Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437-53.
5. Pacurariu AC, Coloma PM, van Haren A, Genov G, Sturkenboom MC, Straus SM. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee. Drug Saf. 2014;37(12):1059-66.
6. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409-19.
7. van Grootheest K, Passier JL, van Puijenbroek E. Direct patient reporting of adverse drug reactions. Drug Saf. 2009;32(1):37-48.
8. Herxheimer A, Crombholz M, Haag M, et al. Yellow card reporting by patients. Clin Med (Lond). 2010;10(3):285-6.
9. Harmark L, Puijenbroek E, Straus S, van Grootheest K. Trends in the use of patient reporting in the Netherlands: more reports, better quality of information. Drug Saf. 2011;34(11):1015-24.
10. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362(10):865-9.
11. US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Rockville, MD: FDA; 2009.
12. Medicines and Healthcare products Regulatory Agency. Yellow Card: guidance on adverse drug reactions. London: MHRA; 2022. Available from: https://yellowcard.mhra.gov.uk
13. Ferrajolo C, Polimeni G, Scondotto G, et al. Drug-related hospital admissions for adverse events in children: an overview of systematic reviews and analysis of Italian data. Paediatr Drugs. 2013;15(3):177-85.
14. US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. Silver Spring, MD: FDA; 2023. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers
15. Uppsala Monitoring Centre. VigiBase. Uppsala: WHO-UMC; 2024. Available from: https://www.who-umc.org/vigibase/vigibase
16. Golder S, Norman G, Loke YK. Systematic review on the prevalence, frequency and comparative value of adverse events data in social media. Br J Clin Pharmacol. 2015;80(4):878-88.
17. Freifeld CC, Brownstein JS, Menone CM, et al. Digital drug safety surveillance: monitoring pharmaceutical products in Twitter. Drug Saf. 2014;37(5):343-50.
18. Sarker A, Ginn R, Nikfarjam A, et al. Utilizing social media data for pharmacovigilance: a review. J Biomed Inform. 2015; 54:202-12.
19. Harpaz R, DuMouchel W, Shah NH, et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010-21.
20. Trifirò G, Crisafulli S, Andersen M, et al. New multidisciplinary research strategies for adverse drug reactions: from genetic background to the use of artificial intelligence. Drug Saf. 2019;42(12):1351-64.
21. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline: electronic transmission of individual case safety reports E2B(R3). Geneva: ICH; 2016.
22. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VI – Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). Amsterdam: EMA; 2017.
23. Kalaiselvan V, Thota P, Singh GN. Pharmacovigilance Programme of India: recent developments and future perspectives. Indian J Pharmacol. 2016;48(6):624-8.
24. Dankar FK, Ibrahim M. Protecting privacy in big data pharmacovigilance: challenges and perspectives. Drug Saf. 2019;42(2):181-90.
25. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-96.
26. Insani WN, Whittlesea C, Alwafi H, et al. Prevalence of adverse drug reactions in the primary care setting: a systematic review and meta-analysis. PLoS One. 2021;16(5): e0252161.
27. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006. Drug Saf. 2009;32(11):1067-74.
28. Ergör G, Ergör A, Baydur H. Digital divide in healthcare. Lancet Digit Health. 2021;3(4):e205-e206.
29. Radin JM, Wineinger NE, Topol EJ, Steinhubl SR. Harnessing wearable device data to improve state-level real-time surveillance of influenza-like illness in the USA: a population-based study. Lancet Digit Health. 2020;2(2):e85-93.
30. US Food and Drug Administration. Sentinel initiative. Silver Spring, MD: FDA; 2023. Available from: https://www.sentinelinitiative.org
31. Banerjee AK, Ingate S, Mayall S. Web-based patient information systems. Pharm Med. 2013;27(5):189-95.
32. Omar IA, Debe M, Jayaraman R, Salah K, Omar M, Arshad J. Blockchain-based supply chain traceability for COVID-19 personal protection equipment. Comput Ind Eng. 2021; 167:107995.